Corning to License Incyte's Gene Patent Portfolio and Gene Sequence Databases for Microarray Commercialization Palo Alto, CA, January 8, 2001 -- Incyte Genomics, Inc. (Nasdaq: INCY), the leading genomic information company, and Corning Incorporated (NYSE: GLW), announced today that they have entered into a licensing agreement granting Corning rights to utilize Incyte's gene sequence databases and gene patent portfolio for the commercialization of microarrays. Financial terms were not disclosed. Under terms of the agreement, Corning will license Incyte's extensive portfolio of patented and proprietary gene sequences to develop, manufacture, and sell microarrays. Corning will access Incyte's LifeSeq® Gold human gene sequence database and Incyte's ZooSeq™ animal model database to manufacture comprehensive human and animal genome microarrays. Incyte will receive royalties on sales of Corning's microarrays developed using Incyte's proprietary databases and technology. As part of an overall strategy to develop new technologies and state-of-the-art tools for life science research, Corning recently announced the development of a novel manufacturing process for the high-volume production of DNA microarrays - used by scientists to simultaneously analyze thousands of genes. Corning launched its first commercial DNA microarray, the CMT™ Yeast Array, in September of last year, and intends to expand its product portfolio with both index and theme arrays for multiple organisms in 2001. "We are pleased to have access to Incyte's gene sequence databases and their extensive collection of high quality clones," said Thomas R. Hinman, Divison Vice President and General Manager, Corning Microarray Technologies. "We believe this agreement will significantly enhance our ability to design and produce microarrays, and continues to strengthen our genetic content access supporting our planned full commercial microarray production in 2001." Researchers using Corning microarrays will be able to link directly to Incyte's LifeSeq® Gene-by-Gene web site to purchase additional information about gene sequences and clones. This "click-through" mechanism enables researchers to quickly and easily obtain information about Incyte's proprietary genes and to order clones and other products for conducting further research. The LifeSeq Gold database features 120,000 gene transcripts, including more than 60,000 not commercially available elsewhere. Based on actual expression rather than prediction, the nearly six million cDNA sequences, 4.6 million of which are proprietary to Incyte, are derived from more than 1,200 different tissue libraries that represent more than 90% of the genes in the human genome. Currently, Incyte holds more than 550 issued and allowed full-length gene patents. As a LifeSeq Gold subscriber, Corning will also have access to the world's largest and most comprehensive set of data on the human genome. LifeSeq Gold contains more full-length genes and related clones than any other competing database product. Established in 1851, Corning Incorporated (www.corning.com) creates leading-edge technologies for the fastest-growing markets of the world's economy. Corning manufactures optical fiber, cable and photonic products for the telecommunications industry; and high-performance displays and components for television and other communications-related industries. The company also uses advanced materials to manufacture products for scientific, semiconductor, environmental and life science markets. Corning's revenues in 1999 were $4.7 billion. Incyte Genomics, Inc. is the leading provider of an integrated platform of genomic technologies designed to aid in the understanding of the molecular basis of disease. Incyte develops and markets genomic databases and partnership programs, genomic data management software, microarray-based gene expression services, related reagents and services. These products, programs and services assist pharmaceutical and biotechnology researchers with all phases of drug discovery and development including gene discovery, understanding disease pathways, identifying new disease targets and the discovery and correlation of gene sequence variation to disease. For more information, visit Incyte's web site at http://www.incyte.com. Except for the historical information contained herein, the matters set forth in this press release, including statements as to potential revenues received on royalties from sales of microarrays, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including, the ability to meet goals of the collaboration; Incyte's ability to enforce drug target patents and changes in laws as they affect such patents; alternative technological advances and competition; and other risks detailed from time to time in Incyte's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2000. Incyte disclaims any intent or obligation to update these forward-looking statements.